key: cord-0898360-0jnqtict authors: Haguet, Hélène; Douxfils, Jonathan; Eucher, Christine; Elsen, Marc; Cadrobbi, Julie; Tré‐Hardy, Marie; Dogné, Jean‐Michel; Favresse, Julien title: Clinical performance of the Panbio assay for the detection of SARS‐CoV‐2 IgM and IgG in COVID‐19 patients date: 2021-03-01 journal: J Med Virol DOI: 10.1002/jmv.26884 sha: 21a90159228182d959406b2cefea3ec136866dc4 doc_id: 898360 cord_uid: 0jnqtict Following the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic, numerous serological tests have been developed, including rapid diagnostic tests. This study aims at assessing the clinical performance of the Panbio immunoglobulin G (IgG)/IgM coronavirus disease 2019 (COVID‐19) test (Abbott), a rapid lateral flow assay for the qualitative detection of IgG and IgM against SARS‐CoV‐2. One hundred and thirty‐eight samples from 95 COVID‐19 patients with a positive SARS‐CoV‐2 reverse‐transcriptase polymerase chain reaction were analyzed to assess the clinical sensitivity. Seventy‐six pre‐COVID‐19 samples were used to evaluate the clinical specificity. Two independent and blinded raters determined visually the presence or absence of the IgG, IgM, and control lines for each test after 10 and 20 min. The sensitivity obtained from collected samples more than 14 days after the onset of symptoms was 95.2% for IgG. IgM was less frequently detected (highest sensitivity of 20.5%). The specificities obtained were 98.7% and 100% for IgG and IgM, respectively. In addition, the sensitivity of the assay was better when the reading was performed at 20 min than at 10 min, whereas the specificity was unchanged. The Panbio COVID‐19 IgG/IgM rapid test detects IgG with high sensitivity 14 days since symptom onset but presents a low sensitivity for IgM. The specificity was excellent for both IgG and IgM. This study was conducted from June 16, 2020 to June 24, 2020. The Panbio IgG/IgM COVID-19 rapid test (Abbott) is a rapid lateral flow assay (LFA) for the qualitative detection of IgG and IgM directed against SARS-CoV-2 in human whole blood, serum, or plasma specimens. The Panbio test was performed according to the manufacturer's instructions for use. Briefly, 10 µl of the sample was applied into the specimen well, and then two drops of buffer were applied. Raters determined visually the presence or absence of the IgG, IgM, and control lines for each test 10 and 20 min after the addition of the buffer. As recommended by the manufacturer, even a slightly colored strip was considered positive. The reverse-transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 determination in respiratory samples (nasopharyngeal swab samples) was performed on the LightCycler® 480 Instrument II (Roche Diagnostics®) using the LightMix® Modular SARS-CoV E-gene set. Two independent and blinded raters determined visually the presence or absence of the IgG, IgM, and control lines for each test after 10 and 20 min. In case of discrepancies, a third blinded and independent rater checked the presence or absence of the lines. Consensus results between all raters were used. The intrarater (10 min vs. 20 min) and the interrater (Rater 1 vs. Rater 2) concordances were determined. Data analysis was performed using GraphPad Prism® software (version 8.2.1) and MedCalc® software (version 14.8.1). Confidence intervals for sensitivity and specificity were "exact" Clopper-Pearson confidence intervals. The Cohen's κ coefficient was used to assess the intra-and interrater concordance. Immunoglobulin M was less frequently detected by the Panbio assay, with sensitivities of 7.3% (95% CI: 2.0%-17.6%) and 20.5% (95% CI: 12.4%-30.8%) for samples the first 14 days and for those obtained more than 14 days since symptom onset, respectively. The highest sensitivity for IgM obtained in a particular category based on the number of days after the symptom onset was 30.8% (95% CI: 9.1%-61.4%) (Figure 1 ). Only one sample was positive for IgM and negative for IgG. The inter-rater variability was excellent when the tests were read at 10 min and 20 min for both IgG (Cohen's κ coefficient at 10 and 20 min were 0.972 and 0.991, respectively) and IgM (Cohen's κ coefficient at 10 and 20 min were 0.945 and 0.974). In addition, the sensitivity of the assay was better when the reading was performed at 20 min than at 10 min (Table 1) , whereas the specificity was unchanged. Cohen's κ coefficients for the different time of reading were lower for IgM than IgG, indicating that the time of reading influence more IgM results than IgG ( Table 1) 10 External validations of these tests are therefore paramount, and plenty of data are arriving in the literature. [3] [4] [5] [6] [7] [8] [11] [12] [13] [14] [15] Given the leading position of Abbott for COVID-19 testing, independent external validation of their assays is mandatory to ensure that the performance is in line with their claims. In our evaluation, the sensitivity obtained for all samples collected more than 14 days after the onset of symptoms was 95.2% for IgG. The Panbio assay showed weak sensitivity for IgM (Figure 1 ). The specificities obtained were 98.7% and 100% and for IgG and IgM, respectively. In the instructions for use, Abbott Diagnostics mentioned a sensitivity and a specificity of 95.8% and 94.0%, respectively. 16 In the manufacturer's study, 48 samples of PCRconfirmed patients and 50 pre-COVID-19 samples were analyzed. Taken apart, IgG had a sensitivity and a specificity of 95.8% and 100%, and IgM a sensitivity and a specificity of 56.3% and 94%. 16 Our results are in agreement with these claims and we even obtained a better specificity for IgM, although the sensitivity was lower than claimed. However, in the information provided by the manufacturer, the details of the studied populations were lacking, that is, timing between symptom onset or since PCR positivity and the blood sampling, as well as the characteristics of samples included for specificity calculation. 16 As observed on other assays and platforms, that is, LFA, ELISA, CLIA, ECLIA, 3, 12, 17, 18 we found that sensitivities before 14 days since symptom onset were not sufficient to be reliably used in clinical practice. We, therefore, recommend obtaining a control or confirmatory sample after 14 days to increase the detection rate. Comparing the clinical performance of these rapid tests is hazardous. Indeed, the design of studies varies widely across studies, that is, number of positive and negative samples, the definition of negative samples, number of days since symptoms or since PCR positivity, and comparison to a neutralization test. Some studies included only a very limited number of patients, 14 included control samples collected during the pandemic period, 5,15 defined different categories since symptom onset (i.e., < or > 7 days, 13 0-6, 7-13, 14-25 days, 12 or 5-9, 10-18 days 14 ), or different categories since RT-PCR positivity. 14 Moreover, as with other rapid LFA, 19 we showed that the result may depend on the reader and on the timing of reading (20 min better than 10 min). The utilization of an automated reader may be useful to decrease the interindividual variation, especially when the colored stripe appears very thin. The Panbio COVID-19 IgM/IgG rapid test presents high sensitivities for IgG 14 days since symptom onset but very low sensitivity for IgM. The specificity was excellent for both IgG and IgM. Further investigations designed to evaluate the clinical performances of Panbio over a longer period of time are needed to further consider its use in seroprevalence studies. The kits used for this investigation were generously provided by Abbott. T A B L E 1 Evaluation of the impact of the rater and the time of reading on the IgG (A) and IgM (B) test results The important role of serology for COVID-19 control Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients Clinical performance of the elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies Advice on the use of point-of-care immunodiagnostic tests for COVID-19 Food Administration Drug. Independent evaluations of COVID-19 serological tests Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2 Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital Clinical performance of different SARS-CoV-2 IgG antibody tests Diagnostic performance of a SARS-CoV-2 IgG/IgM lateral flow immunochromatography assay in symptomatic patients presenting to the emergency department Instructions for use-Panbio IgG/IgM COVID-19 rapid test-REF ICO-T402 Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody Clinical performance of two SARS-CoV-2 serologic assays Head-to-Head comparison of rapid and automated antigen detection tests for the diagnosis of SARS-CoV-2 infection Clinical performance of the Panbio assay for the detection of SARS-CoV-2 IgM and IgG in COVID-19 patients The peer review history for this article is available at https://publons. com/publon/10.1002/jmv.26884 The data used to support the findings of this study are available from the corresponding author upon request. http://orcid.org/0000-0002-3123-5289Jonathan Douxfils https://orcid.org/0000-0002-7644-5298Julien Favresse http://orcid.org/0000-0002-9805-049X